Long-term calcitonin therapy in postmenopausal osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Postmenopausal osteoporosis is a significant health concern characterized by bone loss.
• Estrogen deficiency after menopause leads to increased bone resorption and reduced bone mineral density.

Purpose of the Study:

• To evaluate the efficacy of synthetic salmon calcitonin in treating postmenopausal osteoporosis.
• To assess the impact of calcitonin on total body calcium, bone biopsy parameters, and calcium metabolism.

Main Methods:

• A 2-year controlled study involving 45 postmenopausal women (mean age 65).
• Patients received either synthetic salmon calcitonin (100 units/day) or placebo, alongside vitamin D2 and calcium carbonate supplementation.
• Total body calcium (TBCa) was monitored, and iliac crest bone biopsies were performed.

Main Results:

• Treated patients showed a significantly positive change in TBCa from baseline at 12, 18, and 26 months compared to controls.
• Bone biopsies revealed a greater total bone area and a decreased resorbing surface in the calcitonin group at 2 years.
• Calcitonin treatment transiently decreased serum calcium and increased urinary calcium, suggesting enhanced intestinal calcium absorption.

Conclusions:

• Synthetic salmon calcitonin is effective in increasing total body calcium and improving bone histology in postmenopausal osteoporosis.
• The treatment appears to enhance net intestinal calcium absorption, contributing to increased bone mass.
• Calcitonin offers a potential therapeutic option for managing postmenopausal osteoporosis.